Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:30 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

NCT00002127
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Greenbrae, California • Redwood City, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 5:30 AM EST
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

NCT00000989
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Sargramostim, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional Results available

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

NCT01746420
View directory record Official record
Conditions
Lateral Epicondylitis
Interventions
rhPDGF-BB Injection, Placebo
Drug
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Nov 1, 2026, 5:30 AM EST
Recruiting Not applicable Interventional

Pro-2-Cool Pivotal Trial II

NCT06929923
View directory record Official record
Conditions
Concussion, Mild
Interventions
Pro2Cool Device, Sham Cooling Garment Device
Device
Lead sponsor
TecTraum Inc.
Industry
Eligibility
13 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Ann Arbor, Michigan • Akron, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 1, 2026, 5:30 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

NCT07225088
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Adult
Interventions
DESCANSO/Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English
Behavioral
Lead sponsor
Ponce Medical School Foundation, Inc.
Industry
Eligibility
21 Years to 100 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

NCT06804603
View directory record Official record
Conditions
Obesity
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 3 Interventional Results available

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

NCT00182754
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
octreotide acetate, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
122
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Nov 1, 2026, 5:30 AM EST
Completed Not applicable Interventional

The Clinic Treatment Project

NCT01178554
View directory record Official record
Conditions
Anxiety, Depression, Problem Behavior
Interventions
psychotherapy, evidence-based treatment, modular evidence-based treatment
Behavioral
Lead sponsor
Judge Baker Children's Center
Other
Eligibility
7 Years to 13 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Honolulu, Hawaii • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Nov 1, 2026, 5:30 AM EST
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

NCT01601483
View directory record Official record
Conditions
Nonexudative Age Related Macular Degeneration
Interventions
MC-1101, MC-1101 Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional Results available

Lipid Infusion in Dialysis Patients With Endotoxemia

NCT00506454
View directory record Official record
Conditions
Fatigue, End Stage Renal Disease (ESRD)
Interventions
Lipidose, Placebo
Drug
Lead sponsor
Sepsicure
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

NCT02600494
View directory record Official record
Conditions
Bipolar Depression
Interventions
ITI-007 (Lumateperone), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

NCT02099656
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional Results available

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

NCT02222610
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP)
Drug · Procedure
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

NCT00089180
View directory record Official record
Conditions
Actinic Keratosis, Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
liposomal T4N5 lotion, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Nov 1, 2026, 5:30 AM EST
Completed Not applicable Interventional

An Interactive Education Program to Reduce High Risk Behavior in Adolescents Ph II (iTRAC HERO)

NCT06894277
View directory record Official record
Conditions
Risky Sexual Behavior, Emotion Regulation, Adolescent Behavior
Interventions
iTRAC-HERO
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
12 Years to 14 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma

NCT00116103
View directory record Official record
Conditions
Asthma
Interventions
Tacrolimus Inhalation Aerosol
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Timeline
2005 – 2006
U.S. locations
21
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Nov 1, 2026, 5:30 AM EST
Withdrawn Not applicable Interventional

Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

NCT00084370
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
celecoxib, oophorectomy
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Nov 1, 2026, 5:30 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Executive Function Training for Children and Adolescents

NCT07147894
View directory record Official record
Conditions
Cognitive Change
Interventions
Nongamified N-back training, Gamified N-back training, Multiple Domain Training, Coaching Session
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
12 Years to 17 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 1, 2026, 5:30 AM EST
Terminated Phase 2 Interventional Results available

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

NCT03964337
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
Interventions
Cabozantinib, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 3 Interventional Results available

D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

NCT04411199
View directory record Official record
Conditions
Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Interventions
D-PLEX, Standard of Care (SoC)
Drug · Other
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Augusta, Georgia • New Orleans, Louisiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 1, 2026, 5:30 AM EST
Completed Phase 2 Interventional

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

NCT00234507
View directory record Official record
Conditions
Blepharospasm
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
14
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Nov 1, 2026, 5:30 AM EST
Active, not recruiting Phase 2 Interventional

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Interventions
Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
Drug · Other
Lead sponsor
Rong Zhang
Other
Eligibility
60 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 5:30 AM EST
Active, not recruiting Phase 2 Interventional

A Study of GlcNAc on Tear Production in NGLY1-CDDG

NCT05402345
View directory record Official record
Conditions
NGLY1 Deficiency
Interventions
GlcNAc-GlcN, Placebo
Drug · Other
Lead sponsor
Eva Morava-Kozicz
Other
Eligibility
1 Year to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 1, 2026, 5:30 AM EST
Enrolling by invitation Not applicable Interventional

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

NCT06542939
View directory record Official record
Conditions
Diabetes Mellitus Type II, Hypertension
Interventions
Integrated CHW Intervention, CHW Session 1 Only
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 5:30 AM EST